Key Findings
ey Findings from this Session
- Analysis of the NCCTG N9831 trial, with validation in a real-world Caris cohort, showed that HER2-positive ILC demonstrated increased late recurrence risk despite initial trastuzumab benefit and exhibited a distinct immune landscape.
- Thise study demonstrate how transcriptomic and clinico-genomic analyses can identify distinct biological and immune features in breast cancer, potentially supporting more personalized approaches to risk stratification and therapeutic development.